Coordination chemistry and biology of chelators for the treatment of iron overload disorders
Copyright policy )Coordination chemistry and biology of chelators for the treatment of iron overload disorders
Treatment of the medical condition generally referred to as iron overload through the delivery of chelators has recently received a major boost. In 2005 Novartis gained FDA approval for the drug deferasirox, which may be taken orally. Until this time most patients with Fe overload have had to endure long periods of subcutaneous infusions of the orally ineffective drug desferrioxamine (desferal) which has led to major problems with patient compliance. An effective Fe chelator must possess a number of properties for it to be able to complex Fe in vivo and be excreted intact. This Perspective will provide an overview of the current state of chelators for Fe overload; both those currently approved and those undergoing preclinical development.
- University of Queensland Australia
- University of Queensland Australia
- University of Queensland Australia
Desferrioxamine-b, Models, Molecular, Iron Overload, Pyridones, Chemistry, Pharmaceutical, Complex-formation, Deferoxamine, Ligands, Crystallography, X-Ray, Iron Chelating Agents, Benzoates, Ferric Compounds, Inorganic & Nuclear, Chemistry, Inorganic & Nuclear, Myocardial Iron, Humans, Deferiprone, Deferiprone L1, Triazoles, 540, 250204 Bioinorganic Chemistry, Chemistry, Deferasirox, Crystal-structure, Ferrioxamine-b, 730118 Organs, diseases and abnormal conditions not elsewhere classified, 730118 Organs, diseases and abnormal conditions not elsewhere classified, Orally-active Chelator, Therapy, CX, Thalassemia Major
Desferrioxamine-b, Models, Molecular, Iron Overload, Pyridones, Chemistry, Pharmaceutical, Complex-formation, Deferoxamine, Ligands, Crystallography, X-Ray, Iron Chelating Agents, Benzoates, Ferric Compounds, Inorganic & Nuclear, Chemistry, Inorganic & Nuclear, Myocardial Iron, Humans, Deferiprone, Deferiprone L1, Triazoles, 540, 250204 Bioinorganic Chemistry, Chemistry, Deferasirox, Crystal-structure, Ferrioxamine-b, 730118 Organs, diseases and abnormal conditions not elsewhere classified, 730118 Organs, diseases and abnormal conditions not elsewhere classified, Orally-active Chelator, Therapy, CX, Thalassemia Major
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).72 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!